192 related articles for article (PubMed ID: 17396141)
21. [Quality assured HER2 analysis in breast cancer. Important therapeutic predictive and prognostic factor].
Fernö M; Haglund M; Bendahl PO; Olsson H; Rydén L
Lakartidningen; 2008 Aug 6-19; 105(32-33):2181-4. PubMed ID: 18780693
[No Abstract] [Full Text] [Related]
22. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
[TBL] [Abstract][Full Text] [Related]
23. Institutional quality assurance for breast cancer HER2 immunohistochemical testing: identification of outlier results and impact of simultaneous fluorescence in situ hybridization cotesting.
Green IF; Zynger DL
Hum Pathol; 2015 Dec; 46(12):1842-9. PubMed ID: 26412217
[TBL] [Abstract][Full Text] [Related]
24. The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer.
Diaz LK; Gupta R; Kidwai N; Sneige N; Wiley EL
J Histochem Cytochem; 2004 Apr; 52(4):501-7. PubMed ID: 15034001
[TBL] [Abstract][Full Text] [Related]
25. [Human epidermal growth factor receptor 2 testing in breast cancer].
Ivković-Kapicl T; Knezević-Usaj S
Med Pregl; 2010; 63(1-2):69-74. PubMed ID: 20873313
[TBL] [Abstract][Full Text] [Related]
26. What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.
Umemura S; Osamura RY; Akiyama F; Honma K; Kurosumi M; Sasano H; Toyoshima S; Tsuda H; Rüschoff J; Sakamoto G
Am J Clin Pathol; 2008 Dec; 130(6):883-91. PubMed ID: 19019764
[TBL] [Abstract][Full Text] [Related]
27. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.
Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF
Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453
[TBL] [Abstract][Full Text] [Related]
28. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
Pathol Res Pract; 2020 Nov; 216(11):153155. PubMed ID: 32871536
[TBL] [Abstract][Full Text] [Related]
29. A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.
Powell WC; Hicks DG; Prescott N; Tarr SM; Laniauskas S; Williams T; Short S; Pettay J; Nagle RB; Dabbs DJ; Scott KM; Brown RW; Grogan T; Roche PC; Tubbs RR
Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):94-102. PubMed ID: 17536315
[TBL] [Abstract][Full Text] [Related]
30. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
[TBL] [Abstract][Full Text] [Related]
31. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer.
Giltnane JM; Molinaro A; Cheng H; Robinson A; Turbin D; Gelmon K; Huntsman D; Rimm DL
Arch Pathol Lab Med; 2008 Oct; 132(10):1635-47. PubMed ID: 18834223
[TBL] [Abstract][Full Text] [Related]
32. Comparison of HER2 detection methods between central and regional laboratories in Greece.
Papadopoulos S; Kouvatseas G; Skarlos D; Malamos N; Delliou E; Saratsiotou I; Ardavanis A; Mavroudis D; Skarpidi E; Arapantoni P; Karyda I; Patakioyta F; Aravantinos G; Razis E; Fountzilas G; Kosmidis P
Clin Breast Cancer; 2007 Oct; 7(10):784-90. PubMed ID: 18021480
[TBL] [Abstract][Full Text] [Related]
33. HER2--a discussion of testing approaches in the USA.
Thor A
Ann Oncol; 2001; 12 Suppl 1():S101-7. PubMed ID: 11521714
[TBL] [Abstract][Full Text] [Related]
34. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
[TBL] [Abstract][Full Text] [Related]
35. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.
Roche PC; Suman VJ; Jenkins RB; Davidson NE; Martino S; Kaufman PA; Addo FK; Murphy B; Ingle JN; Perez EA
J Natl Cancer Inst; 2002 Jun; 94(11):855-7. PubMed ID: 12048274
[TBL] [Abstract][Full Text] [Related]
36. Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
Paik S; Bryant J; Tan-Chiu E; Romond E; Hiller W; Park K; Brown A; Yothers G; Anderson S; Smith R; Wickerham DL; Wolmark N
J Natl Cancer Inst; 2002 Jun; 94(11):852-4. PubMed ID: 12048273
[TBL] [Abstract][Full Text] [Related]
37. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
Wang B; Ding W; Sun K; Wang X; Xu L; Teng X
Sci Rep; 2019 Nov; 9(1):16726. PubMed ID: 31723206
[TBL] [Abstract][Full Text] [Related]
38. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
39. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
Hicks DG; Kulkarni S
Am J Clin Pathol; 2008 Feb; 129(2):263-73. PubMed ID: 18208807
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
Perez EA; Press MF; Dueck AC; Jenkins RB; Kim C; Chen B; Villalobos I; Paik S; Buyse M; Wiktor AE; Meyer R; Finnigan M; Zujewski J; Shing M; Stern HM; Lingle WL; Reinholz MM; Slamon DJ
Breast Cancer Res Treat; 2013 Feb; 138(1):99-108. PubMed ID: 23420271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
